Menu
Not yet recruiting NCT07541898

Effects of Berberine on Cardiometabolic Outcomes

No phase Interventional Cardiometabolic Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Berberine, Placebo.
Who it may be relevant to
Registry conditions: Cardiometabolic Syndrome. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effects of Berberine Supplementation on Cardiometabolic Parameters

Overview

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Interventions

  • Dietary supplement Berberine
    Berberine supplement 500 mg 2 x per day
  • Other Placebo
    Placebo control 2 x blinded placebo tablet per day

Primary outcome measures

  • Blood triglycerides [Time frame: Baseline]
  • Blood triglycerides [Time frame: 20-days]
Secondary outcome measures (12)
  • Systolic blood pressure [Time frame: Baseline]
  • Systolic blood pressure [Time frame: 20-days]
  • Diastolic blood pressure [Time frame: Baseline]
  • Diastolic blood pressure [Time frame: 20-days]
  • Percent bodyfat [Time frame: Baseline]
  • Percent bodyfat [Time frame: 20-days]
  • Waist to hip ratio [Time frame: Baseline]
  • Waist to hip ratio [Time frame: 20-days]
  • Blood glucose [Time frame: Baseline]
  • Blood glucose [Time frame: 20-days]
  • Triglyceride glucose index [Time frame: Baseline]
  • Triglyceride glucose index [Time frame: 20-days]

Eligibility criteria

Inclusion criteria

  • Healthy
  • Between 18 \& 65 years
  • Non-smoker
  • BMI < 30
  • Able to give informed consent

Exclusion criteria

  • Pregnancy
  • Diabetes or any other metabolic/ uncontrolled hypertensive conditions
  • Food allergies to berberine
  • Habitual consumption of berberine
  • Not regularly taking medication or antioxidant supplements

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07541898 · Berberine cardiometabolic

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗